Symbols

LYRA

Lyra Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 5

Bearish signal 2

Stock Price Surged Significantly

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Price Hits New Low

Price Hits 52-week Low

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LYRA

Lyra Therapeutics, Inc.

A clinical-stage therapeutics company offering a platform that enable precise, sustained and local delivery of medications to the ear, nose and throat passages and other diseased tissues

Industry

Pharmaceutical

Established Date

11/21/2005

Listing Date

05/01/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.lyratherapeutics.com

Security Type

Common stock

Office address

480 Arsenal Way, Watertown, MA 02472

Business

Introduction

Lyra Therapeutics, Inc., was incorporated as a Delaware corporation on November 21, 2005. The company is a clinical-stage therapeutic company focused on the development and commercialization of novel integrated medicines and delivery solutions for the local treatment of ear patients. The company's proprietary technology platform, XTreo, is designed to deliver drugs directly, accurately and continuously directly to affected tissues with a single administration. The company's initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymer matrices designed to provide sinus access for up to six months of continuous drug therapy for the treatment of chronic sinusitis through brief, non-invasive in-office procedures.

Company Financials

EPS

LYRA has released its 2025 Q3 earnings. EPS was reported at -3.38, versus the expected -4.07, beating expectations. The chart below visualizes how LYRA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LYRA has released its 2025 Q3 earnings report, with revenue of 25.00K, reflecting a YoY change of -87.18%, and net profit of -5.98M, showing a YoY change of 49.60%. The Sankey diagram below clearly presents LYRA's revenue sources and cost distribution.